Assay News and Research

RSS

Apolipoprotein E4 promotes the development of Alzheimer’s disease

Researchers characterize the effects of neuronal apolipoprotein E4 on Alzheimer’s disease-associated pathology.

23 Feb 2023

Following third dose of BNT162b2, adverse events increased in those with prior COVID-19

Previous SARS-CoV-2 infection exacerbates the adverse reactions experienced after receipt of the third booster dose.

23 Feb 2023

Study shows antibody-dependent SARS-CoV-2 transmission and pathogenesis

Researchers reported that some monoclonal nAbs directed against distinct RBD epitopes nested inside the SARS-CoV-2 S could substitute ACE2 as a receptor and support fusion between viral and host cell membranes facilitating viral infectivity.

23 Feb 2023

A possible link between aggregation of SARS-CoV-2 proteins and protein misfolding diseases

A new study in the journal Nature Communications aimed to analyze the aggregation propensity in the proteins of both SARS-CoV-2 and SARS-CoV.

21 Feb 2023

Researchers provide a framework for unifying and categorizing neurodegenerative diseases based on eight hallmarks

Researchers presented eight hallmarks of neurodegenerative diseases (NDDs), their in vivo biomarkers, and interactions to help categorize NDDs and specify patients within a specific NDD.

21 Feb 2023

Propylene glycol prevents airborne transmission of respiratory viruses

Researchers assess the ability of propylene glycol to inactivate infection caused by respiratory viruses and prevent airborne transmission.

20 Feb 2023

Utilizing CRISPR to discover new therapy options for COPD

In this interview, we speak to Ceri Wiggins, a Director at AstraZeneca, about the many applications of CRISPR and its role in discovering new COPD therapies.

From Society for Laboratory Automation and Screening (SLAS) 20 Feb 2023

Prior COVID highly protective against severe disease ten months post-infection

In a recent study published in the Lancet, researchers performed a systematic review of scientific literature published from inception up to September 31, 2022, that documented the reduction in risk of coronavirus disease 2019 (COVID-19) among individuals with a prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vis-à-vis those with no COVID-19 history.

19 Feb 2023

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

Researchers used a non-human primate model to show that Sotrovimab, a commercial mAb also known as Xevudy, was fully effective against SARS-CoV-2 Omicron BA.5 sub-lineage and its derivatives, such as BQ.1.1.

17 Feb 2023

The relationship between antibody titers and incident SARS-CoV-2 infection among recipients of a primary vaccine series

Researchers evaluated whether serologic testing could help estimate the risk of SARS-CoV-2 infection in vaccinated individuals who had not received a booster dose.

17 Feb 2023

Small molecule inhibitor reverses malignant hyper-editing by an inflammation-induced protein isoform

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

16 Feb 2023

Repurposing or improving drugs for spinocerebellar ataxia type 5

A team of researchers has developed a new method to screen FDA-approved drugs to determine if they could be repurposed or improved to help patients with a rare, debilitating disease of the nervous system.

16 Feb 2023

Delayed presentation of MIS-C following COVID-19

Researchers elucidate the pathophysiology of MIS-C and describe the probable reasons for the delayed presentation of the condition following COVID-19.

15 Feb 2023

Jamaican fruit bat's response to SARS-CoV-2 adapted to human

In a recent study posted to the bioRxiv* server, researchers examined the vulnerability of Jamaican fruit bats (Artibeus jamaicensis) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Feb 2023

Bivalent and monovalent mRNA boosters induce similar antibody response against Omicron subvariants

A study conducted by US-based scientists claims that bivalent mRNA booster vaccines do not have any added benefits over monovalent booster vaccines in terms of inducing robust and durable neutralizing antibody response against omicron subvariants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Feb 2023